Heron Therapeutics Inc (FRA:AXD2)

Q3 2025 Heron Therapeutics Inc Earnings Call Transcript

Nov 4, 2025 / 01:30 PM GMT

Release Date Price: €0.9855 (-10.73%)

Transcript 10-Q8-K

Key Points

Positve

Heron Therapeutics Inc (HRTX) successfully completed its financing, allowing management to focus on commercial execution and product growth.
The company reported strong operational and financial performance with total net revenues of $38.2 million for Q3 2025 and $114.3 million year-to-date.
Zendle net sales grew 49% in Q3 2025 compared to Q3 2024, and Apovi sales grew 173% in the same period.
The implementation of new initiatives like the Cross-link Ignite program and the creation of a dedicated sales force for Apovi are beginning to have a meaningful impact.
The introduction of a permanent product-specific J code for Zinerlef is expected to streamline reimbursement and improve access and coverage across both government and commercial payers.

Negative

Gross margin decreased to 68.8% from previous quarters due to a one-time write-off of sussol polymer inventory.
The company faces ongoing competitive pressure, which has historically impacted average selling prices.
Research and development expenses decreased due to timing of expenses, which may indicate a slowdown in new product development.
Heron Therapeutics Inc (HRTX) incurred a net loss of $17.5 million for Q3 2025, primarily due to an $11.3 million loss on debt extinguishment.
The company plans to wind down commercialization of Susol over the next 12 months due to declining sales and competitive pressures.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HRTX.OQ - Heron Therapeutics Inc
Q3 2025 Heron Therapeutics Inc Earnings Call
Nov 04, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by.

Welcome to the Heron Therapeutics Q3 2025 conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you need to press 11 on your telephone. You will then hear an automated message advising your hand is raised.

To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Melissa Drell, executive director of Legal. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.